CDH2 and arrhythmogenic right ventricular cardiomyopathy: In a multicenter ARVC cohort in 2021, 83% of patients with CDH2 mutations experienced persistent ventricular tachycardia and SCD, while the incidence of heart failure was only 8.3% [144].